### Highlights of This Issue  4731

### SPECIAL FEATURES

#### CCR Translations

**4733**  
Prostate Cancer SubtyPINg BiomarkerS and Outcome: Is Clarity EmERGing?  
Steven C. Smith and Scott A. Tomlins  
See related article, p. 4904

**4737**  
Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage  
Karin C. Nitiss and John L. Nitiss  
See related article, p. 4873

#### Molecular Pathways

**4740**  
Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers  
Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

#### CANCER THERAPY: CLINICAL

**4747**  
Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors  
Paul Haluska, Michael Meneeec, Elizabeth R. Pimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso

**4758**  
Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design  
Osama E. Rahma, Emily Gammoh, Richard M. Simon, and Samir N. Khleif

**4768**  
The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials  

**4769**  
Is the “3+3” Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design  
Osama E. Rahma, Emily Gammoh, Richard M. Simon, and Samir N. Khleif

**4770**  
The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials  

**4784**  
A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma  
Motonobu Saito, Kouya Shiraishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Tauta, Kensuke Kumamoto, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris, and Takashi Kohn

### PERSONALIZED MEDICINE AND IMAGING

**4794**  
Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform  
Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jiong Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan

**4806**  
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3'-Deoxy-3'-[18F]-Fluorothymidine Positron Emission Tomography  
Francesca Iommelli, Viviana De Rosa, Sara Gargiulo, Mariarosaria Panico, Marcello Monti, Adelaide Greco, Matteo Gramanzini, Giovanni Ortesecco, Rosa Fonti, Arturo Brunetti, and Silvana Del Vecchio

**4816**  
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment  
Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study


Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter

Nima Sharifi and Richard J. Auchus

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response

Christopher M. Hovens, Matthew K.H. Hong, and Niall M. Corcoran

Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.

Downloaded from clincancerres.aacrjournals.org on July 14, 2017. © 2014 American Association for Cancer Research.